uniQure: EC OK of the first gene therapy for adults with hemophilia B

 Historic approval represents the first gene therapy in Europe to treat hemophilia B and provides a new treatment option for patients that reduces the rate of annual bleeds, reduces or eliminates the need for prophylactic therapy, and generates elevated and sustained factor IX levels ~

~ Approval marks uniQure’s second internally-developed and manufactured gene therapy to achieve licensure in the European Union 

https://www.biospace.com/article/releases/uniqure-announces-the-european-commission-approval-of-the-first-gene-therapy-for-adults-with-hemophilia-b/